Limonene: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Perillyl Alcohol/Limonene |FDA_approval=No (Under investigation for anti-cancer properties) |used_for=Investigational use in recurrent glioma treatment |clinical_trial_phase=Early-stage clinical trials, including studies in Brazil for recurrent glioma |common_side_effects=Gastro-intestinal side effects when administered orally; intranasal administration used to mitigate this |OS_with=Primary GBM: median survival of 5.9 months; Secondary GBM: me...") |
(Updated category= to treatment_category= in TreatmentInfo template) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 9: | Line 9: | ||
|usefulness_rating=3 | |usefulness_rating=3 | ||
|notes=Perillyl Alcohol and Limonene, derived from citrus oils, have shown potential as anti-cancer agents. Clinical trials have explored their efficacy, particularly through intranasal administration to avoid gastro-intestinal side effects. Early findings suggest a degree of effectiveness in stabilizing disease and extending survival in recurrent GBM patients, with noted variance based on tumor type and location. Further research is needed to fully understand their therapeutic potential and optimal administration method. | |notes=Perillyl Alcohol and Limonene, derived from citrus oils, have shown potential as anti-cancer agents. Clinical trials have explored their efficacy, particularly through intranasal administration to avoid gastro-intestinal side effects. Early findings suggest a degree of effectiveness in stabilizing disease and extending survival in recurrent GBM patients, with noted variance based on tumor type and location. Further research is needed to fully understand their therapeutic potential and optimal administration method. | ||
| | |treatment_category=Over-the-Counter Drugs and Supplements | ||
|links= | |links= | ||
|toxicity_level=2 | |||
|toxicity_explanation=Perillyl Alcohol and Limonene, despite being under investigation for anti-cancer properties, are derived from citrus oils and generally are not associated with severe toxic effects. They do result in some gastro-intestinal side effects when administered orally, but these side effects are mitigated by intranasal administration. However, as with any treatment, individual responses may vary. | |||
}} | }} | ||
Latest revision as of 10:27, 12 November 2024
| Property | Information |
|---|---|
| Drug Name | Perillyl Alcohol/Limonene |
| FDA Approval | No (Under investigation for anti-cancer properties) |
| Used for | Investigational use in recurrent glioma treatment |
| Clinical Trial Phase | Early-stage clinical trials, including studies in Brazil for recurrent glioma |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Gastro-intestinal side effects when administered orally; intranasal administration used to mitigate this |
| OS without | Not specified |
| OS with | Primary GBM: median survival of 5.9 months; Secondary GBM: median survival of 11.2 months |
| PFS without | Not specified |
| PFS with | Initial report on recurrent GBM patients showed a PFS-6 value of 48% |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | Perillyl Alcohol and Limonene, despite being under investigation for anti-cancer properties, are derived from citrus oils and generally are not associated with severe toxic effects. They do result in some gastro-intestinal side effects when administered orally, but these side effects are mitigated by intranasal administration. However, as with any treatment, individual responses may vary. |
Notes: Perillyl Alcohol and Limonene, derived from citrus oils, have shown potential as anti-cancer agents. Clinical trials have explored their efficacy, particularly through intranasal administration to avoid gastro-intestinal side effects. Early findings suggest a degree of effectiveness in stabilizing disease and extending survival in recurrent GBM patients, with noted variance based on tumor type and location. Further research is needed to fully understand their therapeutic potential and optimal administration method.
From Ben Williams Book: Not specified
Loading comments...
